(19)
(11) EP 2 222 674 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.01.2016 Bulletin 2016/01

(45) Mention of the grant of the patent:
11.11.2015 Bulletin 2015/46

(21) Application number: 08854698.1

(22) Date of filing: 21.11.2008
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 29/00(2006.01)
 A61K 31/437(2006.01)
A61P 37/00(2006.01)
(86) International application number:
PCT/EP2008/066001
(87) International publication number:
WO 2009/068482 (04.06.2009 Gazette 2009/23)

(54)

AMINO TRIAZOLES AS PI3K INHIBITORS

AMINOTRIAZOLE ALS PI3K-HEMMER

AMINO TRIAZOLES EN TANT QU'INHIBITEURS PI3K

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 27.11.2007 EP 07121607
03.07.2008 US 78006
07.08.2008 US 86963

(43) Date of publication of application:
01.09.2010 Bulletin 2010/35

(73) Proprietor: Cellzome Limited
Brentford, Middlesex TW8 9GS (GB)

(72) Inventors:
  • RAMSDEN, Nigel
    SG8 7QP Royston (GB)
  • BELL, Kathryn
    London, E8 3LT (GB)
  • CANSFIELD, Andrew
    Cambridge, CB22 7QT (GB)
  • TAYLOR, Jess
    Dorking, Surrey, RH4 1JJ (GB)
  • SUNOSE, Mihiro
    Sawston, Cambridge, CB22 3 BD (GB)
  • MIDDLEMISS, David
    CM 23 33 NF Hertfordshire (GB)
  • NEUBAUER, Gitte
    68259 Mannheim (DE)

(74) Representative: Price, Susanna Clare Hopley et al
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A-2007/095588
WO-A1-2009/027283
 WO-A-2008/025821
DD-A- 287 263
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).